What Types of Wounds Does HBOT Treat? A Complete Guide

Hyperbaric oxygen therapy (HBOT) is FDA-cleared for 13 wound-related indications, ranging from diabetic foot ulcers to compromised skin grafts. The strongest clinical evidence supports its use for diabetic lower-extremity wounds, where a 2015 Cochrane review found HBOT significantly improved healing at six weeks (RR 2.35, 95% CI 1.19-4.62). Additional FDA-cleared wound indications include crush injuries, necrotizing soft tissue infections, chronic refractory osteomyelitis, and delayed radiation injury. Not every chronic wound qualifies, but the list is broader than most patients realize. This is one of several recovery scenarios studied with hyperbaric oxygen therapy gaining attention in clinical practice.

Diabetic Foot Ulcers: The Strongest Evidence Base

Diabetic foot ulcers (DFUs) represent HBOT’s most thoroughly studied wound application. Over 150,000 diabetes-related amputations occur annually in the United States, and DFUs precede roughly 85% of them according to the CDC. HBOT addresses the core problem: diabetic patients have impaired oxygen delivery to wound tissue, and breathing 100% oxygen at 2.0-2.4 ATA forces dissolved oxygen into plasma at levels 10-15 times normal.

A landmark randomized controlled trial published in Diabetes Care (2010) found that HBOT-treated DFU patients achieved complete wound healing in 52% of cases versus 29% in controls at one year. The Undersea and Hyperbaric Medical Society (UHMS) lists diabetic wounds of the lower extremity as a primary indication, and Medicare covers HBOT for Wagner grade III or higher DFUs that have failed 30 days of standard wound care.

The typical DFU protocol involves 20-40 sessions at 2.0-2.4 ATA for 90 minutes each, delivered daily five days per week. Response is usually assessed after 20 sessions using transcutaneous oxygen measurements (TCOM). Periwound TCOM values below 40 mmHg at baseline with a rise above 200 mmHg on oxygen challenge indicate a responsive wound. Patients with peripheral arterial disease may need revascularization before HBOT can be effective, because the therapy depends on having at least minimal arterial inflow to deliver oxygenated blood to the wound vicinity.

DFU staging using the Wagner classification system determines both treatment urgency and insurance eligibility. Grade III ulcers (deep ulcers with abscess or osteomyelitis) and grade IV-V ulcers (localized or extensive gangrene) meet Medicare coverage criteria. You can find detailed outcome data in our HBOT diabetic foot ulcer statistics breakdown.

Venous Leg Ulcers: Growing but Mixed Evidence

Venous leg ulcers affect roughly 1% of adults at some point in their lives and account for up to 80% of all lower-extremity ulcers. They result from chronic venous insufficiency, where poor blood return causes elevated pressure in lower-leg veins, eventually breaking down skin tissue. The annual treatment cost for venous ulcers in the US exceeds $14 billion, according to estimates from the Society for Vascular Surgery.

A 2023 systematic review in the Journal of Wound Care found that HBOT reduced ulcer area more effectively than standard compression therapy alone, though sample sizes in available trials remain small. The Hammarlund and Sundberg (1994) RCT in Plastic and Reconstructive Surgery showed a 35.7% reduction in ulcer area in the HBOT group versus 2.7% in controls after 30 sessions. The mechanism is well understood: HBOT stimulates angiogenesis (new blood vessel growth), reduces edema, and enhances collagen synthesis, all of which directly counter the pathophysiology of venous stasis.

Venous leg ulcers are not currently a standalone FDA-cleared HBOT indication, which means insurance coverage is inconsistent. Most clinicians use HBOT for venous ulcers that have failed at least 60-90 days of compression therapy and local wound care. Some wound care centers classify refractory venous ulcers under “problem wounds” for billing purposes, though success rates for insurance approval vary by payer. Protocols range from 17 to 66 sessions depending on ulcer chronicity and size.

Pressure Ulcers: Oxygen-Starved Tissue Over Bony Prominences

Pressure ulcers (formerly called bedsores or decubitus ulcers) form when sustained pressure compresses tissue against bone, cutting off microcirculation. They affect up to 2.5 million patients per year in US acute care settings according to the Agency for Healthcare Research and Quality. Stage III and IV pressure ulcers can reach muscle and bone, and healing often takes months with standard care alone.

HBOT increases tissue oxygen tension in pressure-damaged areas, promotes fibroblast proliferation, and enhances leukocyte bacterial killing. A 2004 study in Plastic and Reconstructive Surgery reported improved healing rates in stage III-IV pressure ulcers treated with adjunctive HBOT compared to standard wound care alone. Additional case series have shown benefit in spinal cord injury patients with chronic sacral pressure ulcers, a population with particularly impaired wound healing due to denervation and immobility.

Pressure ulcers are not among the 14 CMS-approved indications for Medicare HBOT coverage. Treatment is typically considered when ulcers are refractory to at least 30 days of standard care including offloading, debridement, and moist wound management. The primary barrier to wider HBOT use for pressure ulcers is not efficacy but rather the lack of large randomized trials needed to gain FDA clearance and insurance coverage. For a broader look at HBOT wound outcomes, see our wound healing statistics page.

Radiation Wounds: Delayed Tissue Damage Months or Years Later

Radiation therapy saves lives, but it damages blood vessels in the treatment field. This vascular injury can manifest months or even years after radiation ends as osteoradionecrosis (bone death, most commonly in the jaw), soft tissue radionecrosis, or radiation cystitis. The tissue becomes chronically hypoxic because the irradiated microvasculature cannot deliver adequate oxygen. An estimated 5-15% of patients who receive radiation therapy will develop some form of late radiation tissue injury.

HBOT is FDA-cleared for delayed radiation injury and is one of the few treatments that addresses the root cause rather than just managing symptoms. A 2016 Cochrane review by Bennett et al. found that HBOT significantly improved outcomes in radiation proctitis and was beneficial for osteoradionecrosis prevention. The Marx protocol demonstrated that HBOT before dental extraction in irradiated jaw tissue reduced the incidence of osteoradionecrosis from 30% to approximately 5%.

Radiation cystitis (hemorrhagic bladder inflammation from pelvic radiation) responds to HBOT in approximately 80% of cases according to published case series. Radiation proctitis (rectal bleeding and pain from pelvic radiation) shows improvement rates of 65-75% with HBOT in observational studies.

Protocols for radiation wounds typically require 30-60 sessions. The Marx protocol involves 20 sessions before surgery and 10 after. Radiation cystitis protocols average 40-60 sessions. We cover this indication in depth in our HBOT for radiation injury guide.

Crush Injuries and Acute Traumatic Ischemia

Crush injuries involve mechanical force that damages tissue architecture and disrupts blood supply. The resulting compartment syndrome, edema, and ischemia-reperfusion injury can lead to tissue death, infection, and amputation. HBOT is FDA-cleared for crush injuries, compartment syndromes, and other acute traumatic ischemias.

A prospective randomized study by Bouachour et al. (1996) published in the Journal of Trauma found that HBOT-treated crush injury patients required significantly fewer surgeries (1.2 vs. 2.4 mean operations) and had complete wound healing in 94% of cases versus 56% in controls. The treatment must begin early, ideally within 4-6 hours of injury, to maximize benefit. This makes crush injury HBOT a time-sensitive intervention, similar to thrombolytic therapy for stroke.

The mechanism involves three pathways: HBOT reduces edema by vasoconstricting while paradoxically increasing tissue oxygenation (the oxygen window effect), it limits ischemia-reperfusion injury by scavenging free radicals, and it preserves marginally viable tissue that would otherwise die from hypoxia. Military applications of HBOT for blast-related crush injuries have expanded the evidence base, with combat casualty data from Iraq and Afghanistan supporting early hyperbaric intervention for limb salvage in polytrauma patients.

Compromised Skin Grafts and Flaps

Skin grafts and surgical flaps depend on rapid vascularization from the wound bed to survive. When the recipient site has poor blood supply (due to prior radiation, diabetes, peripheral vascular disease, or repeat surgery), graft take rates drop substantially. HBOT is FDA-cleared for compromised grafts and flaps where tissue hypoxia is a documented concern.

A 2013 review in Wounds found that adjunctive HBOT improved salvage rates in compromised flaps by promoting neovascularization at the graft-wound interface. The typical protocol involves starting HBOT within 24-48 hours of graft placement and continuing daily for 10-20 sessions at 2.0-2.4 ATA. For free tissue transfer (microsurgical flaps), HBOT is initiated at the first sign of flap compromise, which may include color changes, temperature drop, or Doppler signal loss in the flap pedicle.

Transcutaneous oximetry (TCOM) is used to determine whether a graft site is hypoxic enough to benefit from HBOT. Periwound TCOM values below 40 mmHg while breathing room air generally indicate a compromised graft that may respond to hyperbaric treatment. Values below 20 mmHg indicate severe compromise where graft survival is unlikely without intervention. Our comprehensive wound healing guide covers graft protocols in more detail.

Necrotizing Soft Tissue Infections

Necrotizing fasciitis and related soft tissue infections spread rapidly along fascial planes, destroying tissue as they go. Mortality rates range from 20% to 40% even with aggressive surgical debridement and IV antibiotics. The infections are caused by Group A Streptococcus, Clostridium species, or polymicrobial flora. HBOT serves as an adjunct (never a replacement for surgery) by delivering oxygen to infected tissue where anaerobic bacteria thrive.

A 2005 retrospective study in Annals of Plastic Surgery found that patients who received adjunctive HBOT had lower mortality (11.9% vs. 34.1%) and required fewer debridements than those treated with surgery alone. The mechanism is threefold: HBOT directly inhibits anaerobic bacterial growth at oxygen tensions above 250 mmHg, enhances neutrophil killing capacity (which requires oxygen for the respiratory burst), and potentiates the activity of certain antibiotics including aminoglycosides and sulfonamides.

Treatment typically involves twice-daily 90-minute sessions at 2.4 ATA during the acute phase, transitioning to daily sessions as infection is controlled. The urgency of HBOT for necrotizing infections is reflected in most hyperbaric facilities treating these patients on an emergent basis, including evenings and weekends. This is always combined with surgical debridement, which remains the primary treatment.

Chronic Refractory Osteomyelitis

Osteomyelitis (bone infection) that persists despite adequate antibiotic therapy and surgical debridement is classified as refractory. The condition is particularly common in diabetic patients with foot ulcers, where bone infection complicates up to 68% of severe wounds. HBOT is FDA-cleared for chronic refractory osteomyelitis as an adjunctive treatment.

The mechanism centers on oxygen-dependent immune function. White blood cells require tissue oxygen tensions above 30-40 mmHg to kill bacteria effectively. Infected bone often has oxygen levels below this threshold due to peri-osteal vascular compromise. HBOT raises periosteal oxygen tension to levels that restore leukocyte bactericidal capacity and enhance osteoclast-mediated removal of dead bone (sequestrum resorption).

Protocols typically involve 20-40 sessions at 2.0-2.4 ATA, integrated with antibiotic therapy and surgical debridement. Success rates in published case series range from 60% to 85% when HBOT is added to standard surgical and antibiotic management. A 2002 review by Mader et al. in Clinical Infectious Diseases established the clinical framework for integrating HBOT into refractory osteomyelitis management that most wound care centers still follow today.

How to Know if Your Wound Qualifies for HBOT

The decision to use HBOT for wound healing follows a specific clinical pathway. Not every chronic wound benefits, and most insurance plans (including Medicare) require documented failure of standard wound care before approving HBOT.

General qualifying criteria include:

• The wound has not responded to at least 30 days of standard wound care (debridement, offloading, moist wound management, infection control)
• The wound falls within an FDA-cleared or UHMS-approved indication
• Transcutaneous oximetry (TCOM) demonstrates wound-area hypoxia (periwound values below 40 mmHg on room air) with a measurable response to oxygen challenge
• The patient has adequate arterial inflow (ankle-brachial index above 0.7 in lower-extremity wounds)
• No absolute contraindications exist (untreated pneumothorax, certain chemotherapy agents like bleomycin or cisplatin)

Your wound care specialist or hyperbaric medicine physician will typically order TCOM testing to confirm that your wound tissue is oxygen-responsive. A positive response (periwound TCOM rising above 200 mmHg when breathing 100% oxygen) suggests HBOT is likely to help. A negative TCOM response does not automatically exclude HBOT, but it does reduce the expected benefit and may complicate insurance approval.

The referral process usually starts with your primary wound care provider (surgeon, podiatrist, or wound care specialist) identifying that standard care has failed. They refer you to a hyperbaric medicine physician who evaluates your wound, orders TCOM testing, and determines whether HBOT is appropriate. Most hospital-based wound care centers have hyperbaric medicine capabilities in-house, streamlining this process.

For information on coverage and costs, see our insurance and Medicare coverage guide.

The Bottom Line on HBOT Wound Types

HBOT has FDA clearance for wound-related conditions spanning diabetic foot ulcers, crush injuries, radiation tissue damage, compromised grafts, necrotizing infections, and chronic osteomyelitis. The strongest evidence supports diabetic foot ulcers and delayed radiation injury. For wounds not on the FDA-cleared list (such as venous ulcers and pressure ulcers), HBOT may still be used off-label, but insurance coverage becomes uncertain and out-of-pocket costs increase significantly.

The common thread across all HBOT wound indications is tissue hypoxia. If a wound is not healing because it lacks oxygen, HBOT can deliver what the damaged vasculature cannot. The first step for any chronic wound patient is a comprehensive vascular and wound assessment with TCOM testing to determine whether hypoxia is a contributing factor.

Seph Fontane Pennock

Author

Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.

Website